IP Library › Granted Patent US 11,390,658
Granted Patent B2
US 11,390,658 · App. 16/307,201 · Granted Jul 19, 2022

Anti-CD7 chimeric antigen receptor and method of use thereof

Inventors: Rafijul Bari (Gaithersburg, MD); Wing Leung (Memphis, TN)
Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
C07K14/7051A61K35/15A61K35/17A61K48/00A61P35/00C07K14/705C07K14/70507C07K14/70514C07K14/70517C07K14/70521C07K14/70578C07K14/70596C07K16/2803A61K38/00C07K2317/55C07K2317/622C07K2319/02C07K2319/03C07K2319/033C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,390,658
App. No.
16/307,201
Granted
Jul 19, 2022
Kind
B2
Abstract

A nucleic acid construct and mammalian cell harboring nucleic acids encoding an anti-CD7 chimeric antigen receptor are provided. Methods for treating cancer, in particular a hematologic cancer, using the nucleic acid construct or mammalian cell are also described.

Claims (8)

1. An isolated nucleic acid construct encoding a chimeric antigen receptor (CAR) comprising an anti-CD7 binding domain, a transmembrane domain, and a cytoplasmic domain, wherein said CAR comprises the amino acid sequence of SEQ ID NO:2.

2. The nucleic acid construct of claim 1 , wherein the construct comprises a vector.

3. A mammalian cell comprising the nucleic acid construct of claim 1 .

4. The mammalian cell of claim 3 , wherein the cell is a T cell, a Natural Killer cell, a cytotoxic T lymphocyte, or a regulatory T cell.

5. A method for producing an anti-CD7 chimeric antigen receptor (CAR) T cell comprising

(a) obtaining a population of CD7-negative T cells; and

(b) transducing the CD7-negative T cells with a nucleic acid construct encoding an anti-CD7 CAR comprising the amino acid sequence of SEQ ID NO:2.

6. A method for treating a CD7 expressing hematological cancer comprising delivering to a subject in need of treatment an effective amount of a T cell, a Natural Killer cell, or a cytotoxic T lymphocyte, said cell comprising the nucleic acid construct of claim 1 , thereby treating the subject's cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2018
From: BARI, RAFIJUL; LEUNG, WING
To: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
Reel/Frame 047677/0880 →
Continuity (2)
Provisional Application 62346092 · Jun 6, 2016
Related Publication 20190144522A1 · May 16, 2019
Cited By (3)
US 12,350,349 US 12,564,648 US 12,629,430